Altimmune
Altimmune's revenue rose 105.0% to $0 million in fiscal 2025. Its operating margin was −230,461.0%, up from −515,860.0% a year earlier. Free cash flow was −$68 million. The diluted share count rose 24.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Altimmune does
Altimmune is a late clinical-stage drug developer, meaning its medicine is in later-stage tests in people and is not approved for sale. It works on treatments for serious liver diseases.
Its lead candidate is pemvidutide, an injected peptide that acts on two hormone receptors, glucagon and GLP-1, at equal strength. It is being studied for MASH, a liver disease caused by fat build-up and inflammation, and for alcohol use disorder and alcohol-associated liver disease. The company says the FDA has granted pemvidutide Breakthrough Therapy and Fast Track designations for MASH, which are programs meant to speed up review of drugs for serious conditions.
Altimmune has no products on the market and so no product sales. It got pemvidutide in 2019 by buying Spitfire Pharma, and it says it holds patents on it that run into the 2040s if expected patent term extensions are included.
Its biggest risks, as it describes them
- It has lost money since it was founded and may never be profitable.
- It will need substantial more financing, which could dilute shareholders or force it to cut programs.
- Pemvidutide and its other candidates may fail in clinical trials or never reach the market.
- Its clinical trials may be delayed, or may not show safety and effectiveness to regulators' satisfaction.
- Making its drug is complex, and it may face production difficulties.
Income statement
Altimmune lost money in fiscal 2025: a net loss of $88 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | — | 185 | 198 | 132 | 274 |
| Debt incl. finance leases | 2 | 5 | — | — | 34 |
| Net debt (negative means net cash) | — | −180 | — | — | −239 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | — | — | 0.1x |
| Interest coverage | −19,382.8x | −10,967.5x | −2,740.8x | −11,463.6x | −57.8x |
| Current ratio | 11.2x | 11.3x | 17.3x | 13.1x | 18.6x |
| Quick ratio | 11.2x | 11.3x | 17.3x | 13.1x | 18.6x |
Cash flow
Projections
Project Altimmune's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Altimmune reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | −164,641.3% |
| Altman Z'' | 8.19 | −3.94 | 0.63 |
| Accruals ratio | −6.0% | −8.7% | −9.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Altimmune side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Altimmune | FY25 | 105.0% | −230,461.0% | −164,746.3% | — | — | — | |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| Alkermes | FY25 | −5.2% | 17.2% | 32.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 3 | 11 | 10 | 6 | 8 | 4 | −0 | 0 | 0 | 0 |
| Revenue growth | — | 231.8% | −3.8% | −43.9% | 41.1% | −46.1% | −101.5% | — | −95.3% | 105.0% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 7 | 18 | 18 | 18 | 50 | 74 | 70 | 66 | 82 | 66 |
| Operating income | −11 | −52 | −43 | −22 | −55 | −97 | −88 | −96 | −103 | −94 |
| Net income | −11 | −46 | −39 | −20 | −49 | −97 | −85 | −88 | −95 | −88 |
| Diluted EPS (US$) | 2.95 | −118.91 | −15.16 | −1.60 | −1.91 | −2.35 | −1.81 | −1.66 | −1.34 | −1.00 |
| Diluted shares (millions) | 66 | 0 | 3 | 13 | 26 | 41 | 47 | 53 | 71 | 88 |
| Cash flow | ||||||||||
| Cash from operations | −6 | −20 | −9 | −10 | −34 | −78 | −63 | −76 | −80 | −68 |
| Capital expenditure | 0 | 0 | 1 | 0 | 0 | 12 | 0 | 0 | — | 0 |
| Free cash flow | −6 | −20 | −10 | −10 | −35 | −90 | −63 | −76 | — | −68 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 1 | 3 | 6 | 8 | 11 | 14 | 16 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 221 | — | 34 | 37 | 216 | — | 185 | 198 | 132 | 274 |
| Debt incl. finance leases | — | 1 | 1 | 2 | 2 | 2 | 5 | — | — | 34 |
| Total assets | 38 | 63 | 55 | 54 | 245 | 219 | 207 | 211 | 139 | 280 |
| Total liabilities | 6 | 14 | 6 | 8 | 19 | 20 | 22 | 16 | 16 | 55 |
| Shareholders' equity | 32 | 39 | 48 | 46 | 226 | 199 | 185 | 194 | 124 | 225 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −342.7% | −484.7% | −414.6% | −370.0% | −669.5% | −2,197.6% | 129,029.4% | −22,518.5% | −515,860.0% | −230,461.0% |
| Net margin | −342.6% | −432.3% | −379.2% | −353.7% | −599.2% | −2,201.6% | 124,577.9% | −20,762.2% | −475,295.0% | −214,861.0% |
| Free cash flow margin | −200.2% | −189.3% | −100.3% | −165.5% | −421.6% | −2,048.9% | 92,223.5% | −17,806.8% | — | −164,746.3% |
| Rule of 40 (growth + FCF margin) | — | 42.5% | −104.1% | −209.4% | −380.5% | −2,095.0% | 92,122.0% | — | — | −164,641.3% |
| Return on capital | — | — | — | −134.0% | — | — | — | — | — | — |
| Return on equity | −29.4% | −129.7% | −89.3% | −43.7% | −36.1% | −45.7% | −44.1% | −46.6% | −59.9% | −50.6% |
| Return on assets | −38.1% | −91.5% | −66.5% | −37.7% | −32.8% | −41.9% | −39.8% | −42.4% | −54.3% | −42.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |